Novavax aims for 2 bn COVID-19 vaccine doses with expanded India deal

U.S. drug developer Novavax Inc said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, sending its shares up about 7%.
Source: The Economic Times - Category: Consumer Health News Source Type: news